As of my last update in October 2023, there is limited publicly available information regarding the chemical substance known as UMB-32, with the CAS number 1635437-39-6. UMB-32 is a compound that has been studied primarily in the context of medicinal chemistry, particularly for its potential applications in neuroscience and pharmacology. It is known to act as a selective inhibitor of certain biological pathways, which may have implications for treating various neurological disorders. The compound's structure and mechanism of action are of interest for research into its efficacy and safety profile. However, specific details regarding its physical and chemical properties, such as solubility, stability, and reactivity, may not be widely documented in public databases. For comprehensive and precise information, including experimental data and safety considerations, consulting specialized scientific literature or databases is recommended.

UMB-32

1635437-39-6: As of my last update in October 2023, there is limited publicly available information regarding the chemical substance known as UMB-32, with the CAS number 1635437-39-6. UMB-32 is a compound that has been studied primarily in the context of medicinal chemistry, particularly for its potential applications in neuroscience and pharmacology. It is known to act as a selective inhibitor of certain biological pathways, which may have implications for treating various neurological disorders. The compound's structure and mechanism of action are of interest for research into its efficacy and safety profile. However, specific details regarding its physical and chemical properties, such as solubility, stability, and reactivity, may not be widely documented in public databases. For comprehensive and precise information, including experimental data and safety considerations, consulting specialized scientific literature or databases is recommended.

<p>UMB-32 is a bromodomain inhibitor. Bromodomains are protein domains that have been shown to be involved in the transcriptional regulation of genes. They bind to acetylated lysine residues on histones and other proteins, which affects the expression of genes. UMB-32 binds to the bromodomain, preventing it from binding with acetylated lysine residues. This prevents gene expression, which interferes with cellular proliferation and development. UMB-32 has been shown to inhibit cancer cells in vitro and in vivo by interfering with the proliferation of cancer cells. It also inhibits HIV infection, as well as combinatorial effects with antiretroviral therapy drugs such as dasatinib or bromosporine.</p>

<p>UMB-32: Potent, selective BRD4 inhibitor, Kd 550 nM, IC50 637 nM, also targets TAF1.</p>

CAS 1635437-39-6

UMB-32

UMB-32

Ref: 3D-KQC43739

UMB-32

Ref: TM-T21920